BR112014002975A2 - biomarker compositions and methods - Google Patents

biomarker compositions and methods

Info

Publication number
BR112014002975A2
BR112014002975A2 BR112014002975A BR112014002975A BR112014002975A2 BR 112014002975 A2 BR112014002975 A2 BR 112014002975A2 BR 112014002975 A BR112014002975 A BR 112014002975A BR 112014002975 A BR112014002975 A BR 112014002975A BR 112014002975 A2 BR112014002975 A2 BR 112014002975A2
Authority
BR
Brazil
Prior art keywords
disease
methods
biomarkers
condition
stages
Prior art date
Application number
BR112014002975A
Other languages
Portuguese (pt)
Inventor
Spetzler David
Brown Kirk
Pawlowski Traci
Original Assignee
Caris Life Sciences Luxembourg Holdings S A R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caris Life Sciences Luxembourg Holdings S A R L filed Critical Caris Life Sciences Luxembourg Holdings S A R L
Publication of BR112014002975A2 publication Critical patent/BR112014002975A2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

biomarker compositions and methods abstract biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease, select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and to determine treatment efficacy. circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. these include nucleic acids, protein, and circulating structures such as vesicles, and nucleic acid-protein complexes. tradução do resumo resumo patente de invenção: "composições de biomarcador e métodos". biomarcadores podem ser avaliados para métodos de diagnóstico, relacionados à terapia ou prognóstico para identificar fenótipos, tal como uma condição ou doença, ou o estágio ou progressão de uma doença, selecionar regimes de tratamento candidatos para doenças, condições, estágios de doença e estágios de uma condição e determinar a eficácia de tratamento. biomarcadores de circulação de um fluido corporal podem ser usados no traçado de perfil de estágios fisiológicos ou determinação de fenótipos. esses incluem ácidos nucleicos, proteína e estruturas de circulação tais como vesículas e complexos de ácido nucleico-proteína.biomarker compositions and methods abstract biomarkers can be evaluated for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or stage of progression of a disease, select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and to determine treatment efficacy. circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. These include nucleic acids, protein, and circulating structures such as vesicles, and nucleic acid-protein complexes. abstract of the patent summary: "biomarker compositions and methods". Biomarkers can be evaluated for diagnostic, therapy, or prognostic methods to identify phenotypes such as a condition or disease, or the stage or progression of a disease, select candidate treatment regimens for disease, conditions, disease stages, and stages of disease. a condition and determine the effectiveness of treatment. Biomarkers of body fluid circulation can be used for physiological stage profiling or phenotype determination. these include nucleic acids, protein and circulation structures such as vesicles and nucleic acid-protein complexes.

BR112014002975A 2011-08-08 2012-08-08 biomarker compositions and methods BR112014002975A2 (en)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201161521333P 2011-08-08 2011-08-08
US201161523763P 2011-08-15 2011-08-15
US201161526623P 2011-08-23 2011-08-23
US201161529762P 2011-08-31 2011-08-31
US201161534352P 2011-09-13 2011-09-13
US201161537462P 2011-09-21 2011-09-21
US201161542639P 2011-10-03 2011-10-03
US201161551674P 2011-10-26 2011-10-26
US201161559676P 2011-11-14 2011-11-14
US201261612111P 2012-03-16 2012-03-16
US201261619803P 2012-04-03 2012-04-03
PCT/US2012/050030 WO2013022995A2 (en) 2011-08-08 2012-08-08 Biomarker compositions and methods

Publications (1)

Publication Number Publication Date
BR112014002975A2 true BR112014002975A2 (en) 2017-03-01

Family

ID=47669214

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014002975A BR112014002975A2 (en) 2011-08-08 2012-08-08 biomarker compositions and methods

Country Status (8)

Country Link
EP (1) EP2742154A4 (en)
JP (1) JP2014522993A (en)
KR (1) KR20140067001A (en)
CN (1) CN103874770A (en)
AU (1) AU2012294458A1 (en)
BR (1) BR112014002975A2 (en)
CA (1) CA2844671A1 (en)
WO (1) WO2013022995A2 (en)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0913578A2 (en) 2008-05-14 2017-06-06 Dermtech Int diagnosis of melanoma and solar lentigo by nucleic acid analysis
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
CA2795776A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
CA2877721A1 (en) 2012-06-27 2014-01-03 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
CN103160509B (en) * 2013-03-07 2015-02-18 新乡医学院第一附属医院 miRNA marker relative to esophagus cancer postoperative early relapse and prognosis and application
RU2018101152A (en) 2013-03-15 2019-02-21 Борд оф Риджентс, Дзе Юниверсити оф Тексас Систем USE OF MICRORNA BIOGENESIS IN EXOSOMES FOR DIAGNOSIS AND TREATMENT
CN104076151B (en) * 2013-03-29 2017-04-12 复旦大学附属华山医院 Kit for early diagnosis of glioma
BR112015027249A2 (en) * 2013-04-29 2017-09-26 Apogenix Gmbh cancer diagnosis method
WO2014183093A1 (en) * 2013-05-10 2014-11-13 University Of Southern California Dna methylation biomarkers for bladder cancer
US10301681B2 (en) * 2013-08-06 2019-05-28 Exosome Diagnostics, Inc. Methods of treating a subject with a high gleason score prostate cancer
US20160319361A1 (en) 2013-08-28 2016-11-03 Caris Life Sciences Switzerland Holdings Gmbh Oligonucleotide probes and uses thereof
WO2015031604A1 (en) * 2013-08-28 2015-03-05 Crown Bioscience, Inc. Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
CN105723221B (en) * 2013-11-06 2018-07-06 Jsr株式会社 Separation method, detection method, signal measuring method, the determination method of disease, the method for evaluating drug effect of disease curative, kit and fluid composition
FR3014198B1 (en) * 2013-12-03 2017-03-03 Biomerieux Sa METHOD FOR ISOLATING EXOSOMES
JP6638917B2 (en) * 2013-12-06 2020-02-05 国立大学法人 東京大学 Valve, fluid control structure, fluid device, and valve manufacturing method
JP2017509351A (en) * 2013-12-30 2017-04-06 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド Prostate cancer gene profile and method of use thereof
WO2015101988A1 (en) 2013-12-31 2015-07-09 Yeda Research And Development Co. Ltd. Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
WO2015117164A1 (en) * 2014-02-03 2015-08-06 Memorial Sloan-Kettering Cancer Center Tumor-associated macrophages and methods and compositions for targeting cancer therapy and identifying potential responders
EP3137909B1 (en) 2014-04-29 2018-06-06 Apogenix AG Diagnostic anti-cd95l antibody
CA2947512A1 (en) * 2014-05-01 2015-11-05 Stichting Vumc Small ncrnas as biomarkers
ES2481819B1 (en) * 2014-06-12 2015-04-01 Sistemas Genómicos, S.L. ASSESSMENT METHOD TO EVALUATE A POSSIBILITY OF BREAST CANCER
JP6824736B2 (en) 2014-06-12 2021-02-03 東レ株式会社 Prostate Cancer Detection Kit or Device and Detection Method
US20160038608A1 (en) * 2014-08-07 2016-02-11 National Taiwan University Silica-based mesoporous carrier and delivery method of using the same
ES2792227T3 (en) * 2014-09-26 2020-11-10 Somalogic Inc Prediction of cardiovascular risk event and uses of it
KR101596166B1 (en) 2014-10-07 2016-02-19 가톨릭대학교 산학협력단 A Use of microRNA for Ddiagnosing and Treating Brest Cancer
CN104313171A (en) * 2014-11-06 2015-01-28 南京大学 MicroRNA molecular marker for diagnosing glioma and application of microRNA molecular marker
US10539566B2 (en) * 2014-12-08 2020-01-21 Berg Llc Use of markers including filamin A in the diagnosis and treatment of prostate cancer
CN105807063B (en) * 2014-12-29 2018-02-06 中国人民解放军第二军医大学 Applications of the CD63 in preparing diagnosis for liver disease kit or preparing prevention or treatment liver diseases medicine
CN104548134A (en) * 2015-01-04 2015-04-29 中国人民解放军第二军医大学 Application of miR-144 and inhibitor thereof
US20180148783A1 (en) * 2015-01-05 2018-05-31 The Johns Hopkins University Method of epigenetic analysis for determining clinical genetic risk
WO2016121821A1 (en) * 2015-01-27 2016-08-04 Jsr株式会社 Separation method, detection method, signal measurement method, method for determining disease, method for evaluating drug efficacy, kit, liquid composition, and analyte diluent
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
IL303543A (en) 2015-02-18 2023-08-01 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
CN107533058A (en) 2015-03-01 2018-01-02 免疫阵列有限公司 Use albumen, peptide and oligonucleotides diagnostic antigen systemic loupus erythematosus
WO2016145128A1 (en) 2015-03-09 2016-09-15 Caris Science, Inc. Oligonucleotide probes and uses thereof
CN104714032B (en) * 2015-04-02 2015-09-16 闫星宇 For mark and the detection reagent thereof of postpartum eclampsia diagnosis
US10857181B2 (en) 2015-04-21 2020-12-08 Enlivex Therapeutics Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
WO2016186215A1 (en) * 2015-05-20 2016-11-24 Jsr株式会社 Separation method, detection method, signal measurement method, disease determination method, drug efficacy assessment method, kit, liquid composition, and specimen diluent
NZ738149A (en) 2015-06-10 2024-02-23 Univ Texas Use of exosomes for the treatment of disease
CN104992058B (en) * 2015-06-25 2017-08-01 成都厚立信息技术有限公司 Disease risks adjust method for establishing model
WO2017004243A1 (en) 2015-06-29 2017-01-05 Caris Science, Inc. Therapeutic oligonucleotides
CN105177117A (en) * 2015-07-03 2015-12-23 张理义 Major depressive disorder biomarker, screening method and kit
CN106350578A (en) * 2015-07-13 2017-01-25 中国人民解放军第二军医大学 Application of NY-ESO-1 in diagnosis and treatment of microsatellite instability intestinal cancer
CA2993652A1 (en) 2015-07-28 2017-02-02 Caris Science, Inc. Targeted oligonucleotides
CN105039342B (en) * 2015-08-06 2017-12-01 李家平 SiRNA and its application of MAT2A gene expressions can be suppressed
US20180231565A1 (en) * 2015-08-09 2018-08-16 Immunarray Ltd Methods for determining the risk of a systemic lupus erythematosus (sle) patient to develop neuropsychiatric syndromes
CN105067822B (en) * 2015-08-12 2017-05-24 中山大学附属肿瘤医院 Marker for diagnosing esophagus cancer
JP6583817B2 (en) * 2015-09-04 2019-10-02 国立大学法人山口大学 Diagnostic markers for tumors in uterine smooth muscle
JP6857185B2 (en) * 2015-09-11 2021-04-14 アプタマー サイエンス インコーポレイテッドＡｐｔａｍｅｒ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． Protein biomarker panel for non-small cell lung cancer diagnosis and non-small cell lung cancer diagnostic method using this
CN108290058B (en) 2015-09-17 2023-05-16 美国安进公司 Predicting clinical response of IL23 antagonists using IL23 pathway biomarkers
EP3165926A1 (en) * 2015-11-06 2017-05-10 Humanitas Mirasole S.p.A. Method for characterization of cell specific microvesicles
US11230735B2 (en) 2015-12-24 2022-01-25 Arizona Board Of Regents On Behalf Of The University Of Arizona Systems and methods for characterizing sepsis
WO2017113565A1 (en) * 2015-12-29 2017-07-06 中国医学科学院肿瘤医院 Kit for auxiliary diagnosis of patient with liver cancer or digestive tract cancer based on protein marker psg3
JP6884155B2 (en) 2016-02-18 2021-06-09 エンリヴェックス セラピューティクス リミテッド Combination immunotherapy and cytokine control therapy for cancer treatment
WO2017161357A1 (en) 2016-03-18 2017-09-21 Caris Science, Inc. Oligonucleotide probes and uses thereof
CN105842461A (en) * 2016-04-30 2016-08-10 广州恒泰生物科技有限公司 Rapid diagnostic kit for uterine sarcoma in early and middle stages and preparation method of kit
IL298701B2 (en) 2016-05-25 2024-03-01 Caris Science Inc Oligonucleotide probes and uses thereof
CN107475356A (en) * 2016-06-08 2017-12-15 益善生物技术股份有限公司 Osteosarcoma circulating tumor cell identification kit
CN105907875A (en) * 2016-06-13 2016-08-31 武汉泰安康生物科技有限公司 Method for screening kidney cancer peripheral blood miRNA marker and kidney cancer marker miR-378
JP6980219B2 (en) * 2016-08-22 2021-12-15 いであ株式会社 How to detect cancer or determine the stage of cancer staging
EP3541958A1 (en) * 2016-11-15 2019-09-25 Ventana Medical Systems, Inc. Compositions and methods for prognosing and treating colorectal cancer
CN108165635B (en) * 2016-12-07 2021-07-13 南京农业大学 KIAA1462 gene promoter region variant site and application thereof in improving egg laying performance of geese
US20210072255A1 (en) 2016-12-16 2021-03-11 The Brigham And Women's Hospital, Inc. System and method for protein corona sensor array for early detection of diseases
CN116908452A (en) * 2016-12-16 2023-10-20 布里格姆及妇女医院股份有限公司 System and method for protein crown sensor array for early detection of disease
CN106636296A (en) * 2016-12-22 2017-05-10 广州医科大学附属肿瘤医院 Application of Hsp27 in tolerance diagnosis and treatment for tongue cancer chemotherapy
CN106501517B (en) * 2016-12-27 2018-05-08 北京蛋白质组研究中心 Detect application of the material of SPARC protein in serum in examination hepatocellular carcinoma kit is prepared
CN106939340A (en) * 2017-03-31 2017-07-11 哈尔滨医科大学 A kind of molecular marked compound related to adenocarcinoma of lung transfer and prognosis and its application
CN106947820B (en) * 2017-04-11 2020-09-29 成都望路医药技术有限公司 Application of VCAN in diagnosis and treatment of colon adenocarcinoma
CN111742370A (en) * 2017-05-12 2020-10-02 密歇根大学董事会 Individual and cohort pharmacological phenotype prediction platform
CN106987649A (en) * 2017-05-31 2017-07-28 上海博慷生物科技有限公司 A kind of primer sets and detection method for being used to detect glioma
CN109085355A (en) * 2017-06-13 2018-12-25 中国医学科学院肿瘤医院 Serum protein markers combine the application in screening lung cancer and diagnosis and treatment
CN107273718A (en) * 2017-06-27 2017-10-20 电子科技大学 A kind of Analysis of Survival Time method of fusion dna methylation characteristic
JP7029719B2 (en) * 2017-08-31 2022-03-04 静岡県 Biomarker
CN107630092B (en) * 2017-10-23 2020-03-31 广州医科大学附属第二医院 Application of miR-505-3p in diagnosis, prognosis and treatment of bone metastasis of prostate cancer
CN111512158B (en) * 2017-12-22 2023-12-12 威斯康星校友研究基金会 Nanoengineered surfaces for cancer biomarker capture
CN107868829B (en) * 2017-12-26 2021-05-18 浙江自贸区锐赛生物医药科技有限公司 Combined reagent and kit for evaluating postoperative recurrence risk of chordoma and application of combined reagent and kit
CN107937621A (en) * 2018-01-12 2018-04-20 南方医科大学皮肤病医院（广东省皮肤病医院、广东省皮肤性病防治中心、中国麻风防治研究中心） The application of miRNA, product and detection method using it
CN108192970A (en) * 2018-01-24 2018-06-22 苏州大学 A kind of diagnosing cancer of liver marker and its application
CN108048460B (en) * 2018-02-01 2021-04-09 浙江大学 Novel molecular marker and application thereof in preparation of kit for head and neck cancer diagnosis and prognosis
US11976332B2 (en) 2018-02-14 2024-05-07 Dermtech, Inc. Gene classifiers and uses thereof in non-melanoma skin cancers
SG11202009696WA (en) 2018-04-13 2020-10-29 Freenome Holdings Inc Machine learning implementation for multi-analyte assay of biological samples
FR3080185A1 (en) * 2018-04-16 2019-10-18 Biomerieux EVALUATION OF THE RISK OF COMPLICATION IN A PATIENT SUSPECTED TO HAVE AN INFECTION HAVING A SOFA SCORE LESS THAN TWO
CN108559778B (en) * 2018-04-28 2020-06-12 北京师范大学 Multiple myeloma molecular typing and application thereof in medication guidance
CN108570501B (en) * 2018-04-28 2020-06-12 北京师范大学 Multiple myeloma molecular typing and application
CN108586579B (en) * 2018-05-11 2021-11-30 京东方科技集团股份有限公司 Quasi-peptide, derivative, salt, preparation method and application thereof
CN108931633B (en) * 2018-05-22 2021-08-27 郑州大学第一附属医院 Gallbladder cancer diagnosis and prognosis judgment marker PIM1
CN108841962B (en) * 2018-08-01 2021-11-19 博奥生物集团有限公司 Non-small cell lung cancer detection kit and application thereof
KR102094608B1 (en) * 2018-08-08 2020-04-23 고려대학교 산학협력단 Method for Providing Information on Classification and Prognosis of Hematologic Malignancy
WO2020032228A1 (en) 2018-08-10 2020-02-13 東レ株式会社 Kit, device and method for detecting prostate cancer
CN109321656B (en) * 2018-10-22 2021-10-01 上海交通大学医学院附属仁济医院 Use of protein DEPDC1 as marker for diagnosing triple-negative breast cancer
KR20210068545A (en) * 2018-11-01 2021-06-09 카오카부시키가이샤 Method for preparing nucleic acid derived from skin cells of a subject
CN109507425A (en) * 2018-11-07 2019-03-22 国家纳米科学中心 Carcinoma of prostate based on the extracellular vesica of thermophoresis recurs monitoring system and method
CN113412274A (en) 2018-11-07 2021-09-17 禧尔公司 Compositions, methods and systems for protein corona analysis and uses thereof
WO2020104588A1 (en) * 2018-11-22 2020-05-28 Institut D'investigació Sanitària Pere Virgili Biomarkers of prostate cancer aggressiveness
CN109609630B (en) * 2018-12-03 2023-01-13 哈尔滨医科大学 Molecular marker for early gastric cancer diagnosis and application thereof
CN109439757A (en) * 2018-12-18 2019-03-08 首都医科大学附属北京佑安医院 Application of the blood plasma excretion body miR-455-3p as early liver cancer diagnosis marker
CN109652504B (en) * 2018-12-27 2021-03-16 杭州迪相实业有限公司 Method for simultaneously detecting exosome membrane protein and mRNA
JP2022517563A (en) * 2019-01-02 2022-03-09 チョーチアン クラウンマブ バイオテック カンパニー リミテッド Treatment of cancer with multi-target kinase inhibitors in combination with protein kinase biomarkers
CN109609653B (en) * 2019-02-12 2019-07-19 山东大学齐鲁医院 The molecular marked compound and its application of diagnosis or treatment glioma
EP3699300A1 (en) * 2019-02-22 2020-08-26 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Seminal mirnas as non-invasive biomarkers for the diagnosis and/or prognosis of prostate cancer
JP2022524641A (en) 2019-03-26 2022-05-09 ダームテック，インク． New gene classifiers and their use in skin cancer
CN110196329A (en) * 2019-05-31 2019-09-03 郑州大学第一附属医院 A kind of cancer of the esophagus early stage combined detection kit
WO2020262374A1 (en) * 2019-06-27 2020-12-30 コニカミノルタ株式会社 Exosome measurement method and exosome measurement kit
CN110279707A (en) * 2019-07-05 2019-09-27 深圳市康宁医院(深圳市精神卫生研究所深圳市精神卫生中心) MiR-212 is preparing the application in the drug for treating habituation
US20220291233A1 (en) * 2019-07-19 2022-09-15 Universiteit Antwerpen Mucin isoforms in diseases characterized by barrier dysfunction
KR102346864B1 (en) * 2019-07-24 2022-01-04 한국전자기술연구원 Biomarker composition for diagnosing or prognostic analysis of bladder cancer, kit comprising the same and method for diagnosing bladder cancer using the same
CN117169534A (en) 2019-08-05 2023-12-05 禧尔公司 Systems and methods for sample preparation, data generation, and protein crown analysis
CN110295228A (en) * 2019-08-05 2019-10-01 中国人民解放军总医院第八医学中心 Detect application of the substance of GATA2 in preparation diagnostic activities kit lungy
CN110551809A (en) * 2019-08-21 2019-12-10 昆明医科大学第一附属医院 Application of miR-124 in spinal cord injury repair
CN110564867B (en) * 2019-10-10 2022-06-24 扬州大学 SNP molecular marker of Qinchuan cattle CFL1 gene and detection method thereof
CN110643672A (en) * 2019-10-15 2020-01-03 西安交通大学 Medical application of high-expression TrkB as novel target point in inhibiting pancreatic cancer metastasis
CN115244149B (en) * 2019-12-27 2023-09-15 关西涂料株式会社 Paint manufacturing method, color data prediction method and computer color matching system
CN111647658B (en) * 2020-06-05 2022-09-27 上海市第一人民医院 Application of LINC00963 related oncogenic axis in early diagnosis and treatment of prostate cancer distant metastasis
CN111690746A (en) * 2020-06-30 2020-09-22 镇江维思生物科技有限责任公司 Platelet RNA marker related to lung cancer and application thereof
CN113940999B (en) * 2020-07-15 2022-11-29 中国农业大学 Application of target point for treating non-alcoholic fatty liver disease
CN112180100A (en) * 2020-09-27 2021-01-05 西安交通大学 Application of TWEAK as molecular marker for identifying different types of psoriasis
CN112255408B (en) * 2020-10-16 2023-04-14 牡丹江医学院 Tumor biomarker and tumor detection kit
CN112285195B (en) * 2020-10-27 2021-08-10 江南大学 Characteristic glycoprotein marker of milk exosome and characteristic marker separation method of milk exosome
CN112433053A (en) * 2020-11-20 2021-03-02 四川大学华西医院 Application of Tetraspin-14 protein detection reagent in preparation of lung cancer screening kit
CN112301133B (en) * 2020-12-01 2021-07-27 江门市中心医院 Application of cholesterol generation gene label in prognosis prediction of young breast cancer patient
KR102427057B1 (en) * 2020-12-04 2022-07-29 전남대학교산학협력단 Biomaker for metastasis prediction or prognosis analysis of Solitary fibrous tumor/hemangiopericytoma and diagnosis method using there of
EP4269613A1 (en) 2020-12-24 2023-11-01 Pontificia Universidad Católica De Chile In-vitro method for diagnosing and predicting the aggressiveness of thyroid cancer, and the precision surgery options and type to be used to remove a tumour from a patient; kit; reagents forming the kit; and use of the reagents and use of molecular markers as part of the method
CN113151460B (en) * 2021-01-29 2022-10-18 复旦大学附属中山医院 Gene marker for identifying lung adenocarcinoma tumor cells and application thereof
CN115166245A (en) * 2021-04-04 2022-10-11 兰州大学第一医院 Application of CLU (CLU) and composition thereof in diagnosis of bile duct cancer and bile duct cancer diagnosis kit
KR102540416B1 (en) * 2021-04-09 2023-06-12 주식회사 애티스랩 Composition or kit for diagnosing cancer and method for diagnosis cancer
CN113125757B (en) * 2021-04-22 2022-10-28 石河子大学 Protein biomarker for early pregnancy diagnosis of sows and method for detecting early pregnancy of sows by using protein biomarker
CN113122544A (en) * 2021-04-25 2021-07-16 杭州广科安德生物科技有限公司 Aptamer specifically binding with TIMP1 protein and application thereof
CN113311166B (en) * 2021-04-28 2022-10-28 新疆农垦科学院 Protein biomarker for diagnosing early pregnancy of sheep and method for detecting early pregnancy of sheep
CN113186267A (en) * 2021-06-07 2021-07-30 上海康黎诊断技术有限公司 Primer-probe combination, kit and method for detecting human CYP2D6 copy number variation and genotyping
CN113687076B (en) * 2021-07-14 2024-03-01 郑州大学 Combined detection serum marker for early diagnosis of lung adenocarcinoma and application thereof
GB202111635D0 (en) * 2021-08-13 2021-09-29 Randox Laboratories Risk prediction model for prostate cancer
WO2023054436A1 (en) * 2021-09-29 2023-04-06 株式会社西尾 Beauty method
WO2023064883A1 (en) * 2021-10-14 2023-04-20 The University Of Chicago Immunotherapeutic methods for treating cancer
WO2023140658A1 (en) * 2022-01-24 2023-07-27 고려대학교 산학협력단 Pharmaceutical composition for diagnosing, preventing or treating sepsis by using brain-derived neurotrophic factor
WO2023169686A1 (en) * 2022-03-10 2023-09-14 Buzzard Pharmaceuticals AB Inhibitor of interleukin-1 receptor type 1 for use in the treatment of cancer
WO2024050856A1 (en) * 2022-09-06 2024-03-14 南京市第一医院 Method and system for assisting blood cell analyzer in determining abnormal platelet aggregation
WO2024091020A1 (en) * 2022-10-26 2024-05-02 연세대학교 산학협력단 Extracellular vesicle-derived mirna gene biomarker for breast cancer diagnosis or recurrence prediction, and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052204A2 (en) * 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
CA2544708A1 (en) * 2003-11-03 2005-05-12 Genenews, Inc. Liver cancer biomarkers
WO2007006408A2 (en) * 2005-07-08 2007-01-18 Bayer Healthcare Ag Methods and kits for predicting and monitoring direct response to cancer therapy
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
EP2092075A2 (en) * 2006-11-06 2009-08-26 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring and treatment of melanoma
EP2117305A4 (en) * 2007-01-26 2011-03-30 Univ Louisville Res Found Modification of exosomal components for use as a vaccine
WO2009015357A1 (en) * 2007-07-25 2009-01-29 University Of Louisville Research Foundation, Inc. Exosome-associated microrna as a diagnostic marker
WO2009065230A1 (en) * 2007-11-23 2009-05-28 British Columbia Cancer Agency Branch Methods for detecting lung cancer and monitoring treatment response
US8617806B2 (en) * 2008-01-25 2013-12-31 Hansabiomed Ou Method to measure and characterize microvesicles in the human body fluids
JP2011524164A (en) * 2008-06-06 2011-09-01 サントル・ナシオナル・ドウ・ラ・ルシエルシユ・シアンテイフイク（セー・エヌ・エール・エス） Use of endolysosomal systems and secretory vesicles (exosome-like) in small RNA based therapeutics and diagnostics and experimental studies of small RNAs
BRPI0919882A8 (en) * 2008-10-30 2017-09-19 Caris Life Sciences Luxembourg Holdings METHODS TO EVALUATE RNA PATTERNS
CN107254538A (en) * 2008-11-12 2017-10-17 卡里斯生命科学瑞士控股有限责任公司 The method and system of phenotype is determined using allochthon
GB0822836D0 (en) * 2008-12-15 2009-01-21 Oxford Biomedica Ltd Method
EP2475989A4 (en) * 2009-09-09 2013-02-27 Gen Hospital Corp Use of microvesicles in analyzing kras mutations
US20110166030A1 (en) * 2009-09-30 2011-07-07 Yixin Wang Prediction of response to docetaxel therapy based on the presence of TMPRSSG2:ERG fusion in circulating tumor cells
WO2011066589A1 (en) * 2009-11-30 2011-06-03 Caris Life Sciences Luxembourg Holdings Methods and systems for isolating, storing, and analyzing vesicles

Also Published As

Publication number Publication date
AU2012294458A1 (en) 2014-02-27
EP2742154A4 (en) 2015-08-12
JP2014522993A (en) 2014-09-08
WO2013022995A2 (en) 2013-02-14
CA2844671A1 (en) 2013-02-14
WO2013022995A3 (en) 2013-04-04
EP2742154A2 (en) 2014-06-18
CN103874770A (en) 2014-06-18
KR20140067001A (en) 2014-06-03

Similar Documents

Publication Publication Date Title
BR112014002975A2 (en) biomarker compositions and methods
BR112013032232A2 (en) Cancer characterization method using nucleic acid biomarker
BR112013031591A2 (en) circulation biomarkers for cancer
BR112012025593A2 (en) circulating biomarkers for disease
WO2013134786A3 (en) Biomarker compositions and methods
WO2014193999A3 (en) Biomarker methods and compositions
BR112015023783A2 (en) Method for diagnosis and treatment of cancer metastasis
BR112014031414A2 (en) methods of detecting disease or conditions using circulating diseased cells
EA200901550A1 (en) METHODS OF TREATMENT, DIAGNOSIS AND DETECTION ASSOCIATED WITH FGF21 DISTURBANCES
BR112013023724A2 (en) methods for treating disease or symptom, screening for an agent or a combination of agents, and for determining the effectiveness of an agent and treatment
BR112012022943A2 (en) imidazopyridnas syk inhibitors
WO2013022953A3 (en) Biomarker for alzheimer's disease and/or mild cognitively impairment, and use thereof
BR112015007144A2 (en) use of masitinib for cancer treatment in patient subpopulations identified using predictive factors
WO2011133477A3 (en) Compositions and methods for prediction of drug sensitivity, resistance, and disease progression
BR112015023699A2 (en) method of determining a level of expression of a fibrotic pulmonary disease marker protein, method of determining whether an individual has or is at risk of developing fibrotic pulmonary disease, method of determining whether a patient of fibrotic pulmonary disease is at risk of progression of fibrotic pulmonary disease, method of determining fibrotic pulmonary disease activity in a patient, and method of treating fibrotic pulmonary disease in an individual in need thereof
JP2016536303A5 (en)
EP3879269A3 (en) Methods of measuring signaling pathway activity for selection of therapeutic agents
BR112012030838A2 (en) isolated nucleic acid molecule encoding a mutant mek1 protein having mek1 activity, expression vector, host cell, method of producing a mutant mek1 protein, isolated mutant mek1 protein, method of identifying a patient who has cancer, method of optimizing treating a cancer patient, and using a raf inhibitor and a mek inhibitor.
Dale et al. Background differences in baseline and stimulated MMP levels influence abdominal aortic aneurysm susceptibility
ATE454465T1 (en) IN VITRO METHOD FOR IDENTIFYING COMPOUNDS FOR CANCER THERAPY
WO2009015050A3 (en) Gene expression profile for predicting ovarian cancer patient survival
EA201792669A1 (en) IGFBP3 AND ITS APPLICATION
EA201790563A1 (en) APPLICATION OF WOODLIZUMAB FOR THE TREATMENT OF EOSINOPHIL ASTHMA WITH A DEGREE OF DIFFERENCE TO HEAVY
BR112012026224A2 (en) methods for treating alzheimer's disease and for evaluating the effectiveness of a
BR112015021507A2 (en) methods and compositions for the diagnosis of preeclampsia

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: CARIS LIFE SCIENCES SWITZERLAND HOLDINGS GMBH (CH)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: CARIS LIFE SCIENCES SWITZERLAND HOLDINGS GMBH (CH)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2474 DE 05-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.